about
Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.Incidence, detection, and tumour stage of breast cancer in a cohort of Italian women with negative screening mammography report recommending early (short-interval) rescreen.First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction.miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.RANKL: A promising circulating marker for bone metastasis responseMetronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic ImplicationsUrine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?Effectiveness of service screening: a case–control study to assess breast cancer mortality reduction.The challenge of sustainability in healthcare systems: frequency and cost of diagnostic procedures in end-of-life cancer patients.Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT.Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?Biofunctional characteristics of in situ and invasive breast carcinoma.Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in ItalyGrading of Neuroendocrine Carcinomas: Correlation of Ga-PET/CT Scan with Tissue BiomarkersReceipt of adjuvant systemic therapy among patients with high-risk breast cancer detected by mammography screeningIncidence of interval breast cancers after 650,000 negative mammographies in 13 Italian health districtsBOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study)
P50
Q33442504-F15B2C03-082C-4E51-9CB7-43C4BA5D2329Q33528151-2D02F0BB-7710-41C8-8552-65BD498405CEQ36352317-28EF4056-FA21-45F4-A8A2-D395C22A9C3FQ36858064-4B9694EA-7C7C-4AB0-81BD-641F7DF547F8Q36900550-06FC8B5F-2598-4937-865A-37563FE555FFQ37288243-8C32BC6A-DD8C-4F21-B372-8CF0BA8A5C91Q37637994-28B1DD1E-E292-49D6-92B5-4EAF2A0CD6C5Q37725496-47CA8A69-CB54-48BF-881B-24465FCAA316Q39070963-54CB5B93-F7C9-46C7-83E0-42A1FEFC5C40Q39876681-CFA121BB-032A-431D-9AB5-FCCC6A48D797Q40985522-E4A9742A-C0FC-4416-9694-C3F50DBA4D4CQ41339288-182293D3-FF15-4DD2-9D6D-23E683560A84Q43169980-473FAD5B-516C-4DEE-9F30-13C7A69E653AQ43524369-6F5FF22C-358A-41B2-8039-AE4ABA9EADF9Q45755989-20F95490-C116-4920-9BC4-122E543ACAF6Q48127962-CC092571-7031-44DC-B875-581637D488AEQ48201952-1196F155-3C7C-4B37-AF19-DA9F3DEC858EQ51546513-4EE79E07-DFAA-40B2-858C-5D26503FF269Q52958523-0C056986-9F08-42CE-9439-CA75BFD1D3C7Q54406671-8E53C13E-FFB8-41C7-9CBD-B018A849AA9FQ54423107-31D6C1D2-CBFE-44A0-8448-8BCC34D109C6Q59211747-C7504B59-5164-4594-85C5-474778ADE19FQ60921527-0485DEA8-22A2-4939-84D0-85E844076AFEQ80814645-2B5A84D2-CCB1-4FE4-9764-C7013AF85B38Q81097108-1DEB5238-5B2D-4063-8309-1BB9BD26A089Q91169040-8817ACA1-BE87-444C-89BA-8ACA8778A1A3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Flavia Foca
@ast
Flavia Foca
@en
Flavia Foca
@es
Flavia Foca
@nl
Flavia Foca
@sl
type
label
Flavia Foca
@ast
Flavia Foca
@en
Flavia Foca
@es
Flavia Foca
@nl
Flavia Foca
@sl
prefLabel
Flavia Foca
@ast
Flavia Foca
@en
Flavia Foca
@es
Flavia Foca
@nl
Flavia Foca
@sl
P106
P1153
24171422200
P21
P31
P496
0000-0002-5529-4769